Stay updated on 89Zr-Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the 89Zr-Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a change in the number of PET scans for subsequent patients in a study involving 89Zirconium-labeled Pembrolizumab as a predictive imaging biomarker in patients with non-small-cell lung cancer.
    Difference
    0.1%
    Check dated 2024-06-06T15:59:36.000Z thumbnail image
  4. Check
    5 days ago
    No Change Detected
  5. Check
    6 days ago
    No Change Detected
  6. Check
    18 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    47%
    Check dated 2024-05-22T12:51:44.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Summary
    The value 'Go to the classic website Go to the classic website 5 2' on the webpage has been updated to 'type of intervention Site Map 6 0'. This change likely indicates a modification related to medical and healthcare-related publications and documentation.
    Difference
    1.0%
    Check dated 2024-05-01T17:38:56.000Z thumbnail image

Stay in the know with updates to 89Zr-Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.